期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 282, 期 -, 页码 92-96出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2015.03.021
关键词
Intravenous immunoglobulin; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Relapse rate
资金
- Singapore National Medical Research Council [IRG 10nov086, CSA/047/2012]
Objectives: To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs). Methods: Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded. Results: Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years. Conclusion: IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据